Insu Therapeutics

Insu Therapeutics is a Vancouver-based biotechnology company and University of British Columbia spin-off developing needle-free buccal formulations for peptide medicines. Its proprietary mucoadhesive delivery technology is intended to administer peptide drugs across the inner-cheek mucosa, avoiding gastrointestinal degradation and first-pass hepatic metabolism. The company’s lead investigational programs are InsuTab, a buccal insulin formulation, and BuccaGLP, a buccal semaglutide formulation, initially targeting diabetes and obesity. Insu holds an exclusive worldwide license from the University of British Columbia for the underlying technology and has received a U.S. patent Notice of Allowance covering its layered, unidirectional peptide-release dosage form. (prnewswire.com)